Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
03 May 1993Website:
http://www.anikatherapeutics.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ANIK Latest News
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2023 Earnings Conference Call November 2, 2023 5:30 PM ET Company Participants Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communications Cheryl Blanchard - President & Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Mike Petusky - Barrington Research George Sellers - Stephens Inc Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode.
The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Anika (ANIK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.20 per share a year ago.
Anika Therapeutics Inc. (NASDAQ:ANIK ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard - President, CEO & Director Michael Levitz - Executive VP, CFO & Treasurer Conference Call Participants Harrison Parsons - Stephens Mike Petusky - Barrington Research Jim Sidoti - Sidoti Operator Good afternoon, ladies and gentlemen, and welcome to Anika's First Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded on Tuesday, May 9, 2023.
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.20 per share a year ago.
What type of business is Anika Therapeutics?
Anika Therapeutics, Inc. is an American manufacturer of drugs for preserving and restoring joints. The company was founded in 1992, with headquarters in Bedford, Massachusetts. Anika's proprietary technologies for modifying hyaluronic acid, which are protected by patents, allow for the effective alteration and adaptation of product properties. Anika's products include drugs for relieving joint pain; drugs, implants, surgical instruments for preserving and restoring joints; products for wound care, treatment of ENT diseases; ophthalmic drugs.
What sector is Anika Therapeutics in?
Anika Therapeutics is in the Healthcare sector
What industry is Anika Therapeutics in?
Anika Therapeutics is in the Medical Instruments & Supplies industry
What country is Anika Therapeutics from?
Anika Therapeutics is headquartered in United States
When did Anika Therapeutics go public?
Anika Therapeutics initial public offering (IPO) was on 03 May 1993
What is Anika Therapeutics website?
https://www.anikatherapeutics.com
Is Anika Therapeutics in the S&P 500?
No, Anika Therapeutics is not included in the S&P 500 index
Is Anika Therapeutics in the NASDAQ 100?
No, Anika Therapeutics is not included in the NASDAQ 100 index
Is Anika Therapeutics in the Dow Jones?
No, Anika Therapeutics is not included in the Dow Jones index
When does Anika Therapeutics report earnings?
The next expected earnings date for Anika Therapeutics is 08 August 2024